An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy

Abstract

María Laura Acosta-Felquer, Javier Rosa, Enrique R SorianoRheumatology Unit, Internal Medical Services, and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, ArgentinaAbstract: Certolizumab pegol (CZP) is a pegylated humanized tumor necrosis factor-α inhibitor (TNFi) approved for the treatment of psoriatic arthritis (PsA) in Europe, the USA, and Latin American countries. CZP neutralizes TNF-α at its soluble and membrane portions. Due to the lack of Fc region, it does not induce complement or antibody-dependent cytotoxicity in vitro, unlike other TNFi. RAPID-PsA study, the only randomized clinical trial performed in PsA, is a Phase III clinical trial conducted in 409 PsA patients during 24 weeks. Patients were randomized to CZP (200 mg every 2 weeks or 400 mg every 4 weeks) or placebo. Patients in CZP arms reported improvements in skin disease, joint involvement, dactylitis, enthesitis, and quality of life. Safety profile was similar to that reported for other TNF-α inhibitors in PsA patients. This article summarizes the pharmacology and reviews the efficacy and tolerability of this drug in PsA. CZP is the newest TNFi with proved efficacy in all manifestations of psoriasis disease, except for axial involvement where the evidence has been derived from response to axial spondyloarthritis.Keywords: certolizumab pegol, tumor necrosis factor- inhibitors, psoriatic arthritis, efficacy, safety

Keywords

• certolizumab pegol
• tumour necrosis factor alpha inhibitors
• psoriatic arthritis
• efficacy
• safety.